Advertisement

Topics

Aimmune's peanut allergy therapy closes in on approval with promising Phase 3 data

06:42 EDT 26 Mar 2019 | Pharmafile

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new data which indicated that the drug met its primary endpoint, enabling allergic patients to tolerate approximately three to four peanut kernels.

According to the Phase 3 data, the proportion of patients who were able to tolerate a 1,000mg dose of peanut protein after receiving AR101 for around nine months of treatment was “significantly higher” compared to placebo.

Image caption: 
Image Credit: Alpha Stock Images: http://alphastockimages.com/ Nick Youngson: http://nyphotographic.com/

read more

Original Article: Aimmune's peanut allergy therapy closes in on approval with promising Phase 3 data

NEXT ARTICLE

More From BioPortfolio on "Aimmune's peanut allergy therapy closes in on approval with promising Phase 3 data"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...